-
公开(公告)号：US20230374104A1
公开(公告)日：2023-11-23
申请号：US18030476
申请日：2021-10-07
发明人： Michael C. Jensen , Adam Johnson , James Rosser
IPC分类号： C07K14/705 , C07K14/725
CPC分类号： C07K14/70596 , C07K14/7051
摘要： Some embodiments of the methods and compositions provided herein relate to chimeric proteins comprising a programmed cell death protein 1 (PD 1) extracellular domain and an intracellular immunostimulatory domain. Some embodiments include a cell containing a PD 1 chimeric polypeptide and a chimeric antigen receptor (CAR). In some embodiments, the CAR comprises a ligand binding domain capable of specifically binding to a target antigen on a solid tumor. More embodiments relate to therapies to treat, inhibit or ameliorate certain disorders, such as a cancer, such as a solid tumor.
-
2.发明申请公开(公告)号：US20190016776A1
公开(公告)日：2019-01-17
申请号：US16069485
申请日：2017-01-10
发明人： Michael C. Jensen , Adam Johnson
IPC分类号： C07K14/705 , C07K14/56
摘要： The present application relates to fusion proteins, chimeric antigen bearing cells expressing fusion proteins and compositions comprising chimeric antigen bearing cells expressing fusion proteins. The application further relates to methods of using the fusion proteins, cells and compositions for modulating an immune response.
-
公开(公告)号：US20210324083A1
公开(公告)日：2021-10-21
申请号：US17271813
申请日：2019-08-29
发明人： Adam Johnson , Michael C. Jensen
IPC分类号： C07K16/28 , C07K14/705 , C07K14/725 , C07K14/71
摘要： Embodiments of the methods and compositions provided herein relate to chimeric antigen receptors (CARs) that specifically bind to B7H3. Some embodiments relate to cell-based immunotherapy targeting tumors, such as tumors comprising B7H3+ cells.
-
4.发明申请公开(公告)号：US20210269502A1
公开(公告)日：2021-09-02
申请号：US17165119
申请日：2021-02-02
发明人： Michael C. Jensen , Adam Johnson
IPC分类号： C07K14/705 , C07K14/56 , C07K14/555 , C07K14/725
摘要： The present application relates to fusion proteins, chimeric antigen bearing cells expressing fusion proteins and compositions comprising chimeric antigen bearing cells expressing fusion proteins. The application further relates to methods of using the fusion proteins, cells and compositions for modulating an immune response.
-
公开(公告)号：US20210002364A1
公开(公告)日：2021-01-07
申请号：US16794673
申请日：2020-02-19
发明人： Michael C. Jensen , Adam Johnson
IPC分类号： C07K16/28 , A61K35/17 , C12N5/0783 , C07K14/725 , C07K14/705 , C12N15/85 , A61K35/28 , A61K38/17 , C07K14/71 , C07K14/715 , C07K16/32 , A61K39/395 , C12N9/12
摘要： The present invention provides genetic tags operably linked to transgenes. The expression of the genetic tag allows identification, detection, selection, and ablation of cells expressing the transgene and the genetic tag. In some alternatives the genetically modified host cell comprises a transgene comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain and a polynucleotide coding for a genetic tag. In some alternatives the genetically modified host cell comprises a transgene comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain and a polynucleotide coding for a genetic tag, and wherein the polypeptide further comprises a flexible linker comprising amino acids GGGSGGGS (SEQ ID NO:45). Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
-
公开(公告)号：US20220380461A1
公开(公告)日：2022-12-01
申请号：US17812848
申请日：2022-07-15
发明人： Michael C. Jensen , Adam Johnson
IPC分类号： C07K16/28 , A61K35/28 , A61K38/17 , A61K39/395 , C07K14/725 , C07K14/705 , C07K14/71 , C07K14/715 , C07K16/32 , C12N5/0783 , C12N9/12 , C12N15/85 , A61K35/17
摘要： The present invention provides genetic tags operably linked to transgenes. The expression of the genetic tag allows identification, detection, selection, and ablation of cells expressing the transgene and the genetic tag. In some alternatives the genetically modified host cell comprises a transgene comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain and a polynucleotide coding for a genetic tag. In some alternatives the genetically modified host cell comprises a transgene comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain and a polynucleotide coding for a genetic tag, and wherein the polypeptide further comprises a flexible linker comprising amino acids GGGSGGGS (SEQ ID NO:45). Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
-
公开(公告)号：US20210017246A1
公开(公告)日：2021-01-21
申请号：US16979475
申请日：2019-03-12
IPC分类号： C07K14/54 , C07K14/725
摘要： Some embodiments of the methods and compositions provided herein include cells having membrane-tethered, IL13 mutein-directed zetakine receptors, such as those which specifically bind to the IL-13 receptor alpha 2 (IL13Ra2) at a 50-fold higher affinity than wild-type IL-13, and methods of cell-based immunotherapy targeting cancer cells, such as cells of solid tumors, using these compositions. In some embodiments, the receptors include spacer regions, such as particular spacer regions designed to provide certain advantages.
-
公开(公告)号：US20230212257A1
公开(公告)日：2023-07-06
申请号：US18000468
申请日：2021-06-07
发明人： Michael C. Jensen , Adam Johnson
IPC分类号： C07K14/725 , C07K16/28
CPC分类号： C07K14/7051 , C07K16/2803 , C07K2319/03 , C07K2319/02
摘要： Embodiments of the methods and compositions provided herein relate to anti-CD171 chimeric antigen receptors (CARs). Some embodiments relate to anti-CD171 CARs having long extracellular polypeptide spacers. Some embodiments relate to cells containing such anti-CD171 CARs having increased persistence and activity at a lower dose in a subject compared to cells containing anti-CD171 CARs comprising shorter polypeptide spacers.
-
公开(公告)号：US20170267742A1
公开(公告)日：2017-09-21
申请号：US15302420
申请日：2015-04-08
发明人： Michael C. Jensen , Adam Johnson
IPC分类号： C07K14/71 , C12N5/0783 , C12N9/12 , A61K35/17 , A61K39/395
摘要： The present invention provides genetic tags operably linked to transgenes. The expression of the genetic tag allows identification, detection, selection, and ablation of cells expressing the transgene and the genetic tag. In some alternatives the genetically modified host cell comprises a transgene comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain and a polynucleotide coding for a genetic tag. In some alternatives the genetically modified host cell comprises a transgene comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain and a polynucleotide coding for a genetic tag, and wherein the polypeptide further comprises a flexible linker comprising amino acids GGGSGGGS (SEQ ID NO: 45). Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.033 秒)
